



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 200535

NDA APPROVAL

Lehigh Valley Technologies, Inc.
514 North 12th Street
Allentown, PA 18102

Attention: William Reightler
Director QA/Regulatory Affairs

Dear Mr. Reightler:

Please refer to your new drug application (NDA) dated December 22, 2009, received December 22, 2009, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA), for Oxycodone Hydrochloride Oral Solution, 100 mg/5mL (20 mg/mL).

We acknowledge receipt of your amendments dated January 8, February 23, March 3 and 30, April 5 and 21, June 9, August 16 and 19, September 2, 8, 21, 28, and 30, and October 1 (2), 4, 7, and 15, 2010.

This new drug application provides for the use of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL (20 mg/mL), for the management of moderate-to-severe acute and chronic pain in opioid-tolerant patients.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert, text for the patient instructions for use, and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels, except with the revisions listed below, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 200535**” Approval of this submission by FDA is not required before the labeling is used.

Carton Label

We remind you of your agreement to extend the color box of the product strength across the width of the principal display panel.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PROPRIETARY NAME

If you choose to use a proprietary name for this product, the name and its use in the labels must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit as a Prior Approval Supplement any proprietary name to the Agency for our review prior to its implementation.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are deferring submission of your pediatric study because this product is ready for approval for use in adults and the pediatric study has not been completed.

Your deferred pediatric studies required under section 505B(a) of the FDCA are required postmarketing studies. The status of these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(3)(B) of the FDCA. The required studies are listed below.

1695-1 Pharmacokinetic, safety, and efficacy study in subjects from birth to 2 years of age.

Final Protocol Submission: August 2011
Trial Completion: November 2014
Final Report Submission: November 2015

1695-2 Pharmacokinetic and safety study in subjects >2 years to <17 years of age.

Final Protocol Submission: May 2011
Trial Completion: November 2013
Final Report Submission: May 2014

Submit final study reports to this NDA. For administrative purposes, all submissions related to this required pediatric postmarketing study must be clearly designated “**Required Pediatric Assessment(s).**”

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitment in your submission dated October 7, 2010. This commitment is listed below.

1695-3 Provide the method (or methods) that will be used for the demonstration of the absence of (b) (4) in Oxycodone Hydrochloride Oral Solution drug product(s). Provide sufficient data to validate the ability of the assay to detect (b) (4) if present, as well as document the limit(s) of detection. The USP General Chapters <1227>VALIDATION OF MICROBIAL RECOVERY FROM PHARMACOPeIAL ARTICLES and <1223> VALIDATION OF ALTERNATIVE MICROBIOLOGICAL METHODS may provide useful guidance.

Final Report Submission: March 31, 2011

Submit clinical protocols to your IND 078624 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing

commitments should be prominently labeled “**Postmarketing Commitment Protocol,**” “**Postmarketing Commitment Final Report,**” or “**Postmarketing Commitment Correspondence.**”

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

Section 505-1 of the FDCA authorizes FDA to require the submission of a Risk Evaluation and Mitigation Strategy (REMS) if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks (section 505-1(a)). The details of the REMS requirements were outlined in our REMS notification letter dated May 26, 2010.

Your proposed REMS, submitted on June 9, 2010, and appended to this letter, is approved. The REMS consists of the Medication Guide included with this letter and a timetable for submission of assessments of the REMS.

The REMS assessment plan should include but is not limited to the following:

- a. An evaluation of patients’ understanding of the serious risks of Oxycodone Hydrochloride Oral Solution.
- b. A report on periodic assessments of the distribution and dispensing of the Medication Guide in accordance with 21 CFR 208.24.
- c. A report on failures to adhere to distribution and dispensing requirements, and corrective actions taken to address noncompliance.

Assessments of an approved REMS must include, under section 505-1(g)(3)(B) and (C), information on the status of any post-approval study or clinical trial required under section 505(o) or otherwise undertaken to investigate a safety issue. With respect to any such post-approval study, you must include the status of such study, including whether any difficulties completing the study have been encountered. With respect to any such post approval clinical trial, you must include the status of such clinical trial, including whether enrollment has begun, the number of participants enrolled, the expected completion date, whether any difficulties completing the clinical trial have been encountered, and registration information with respect to requirements under subsections (i) and (j) of section 402 of the Public Health Service Act. You can satisfy these requirements in your REMS assessments by referring to relevant information included in the most recent annual report required under section 506B and 21 CFR 314.81(b)(2)(vii) and including any updates to the status information since the annual report was prepared. Failure to comply with the REMS assessments provisions in section 505-1(g) could result in enforcement action.

We remind you that in addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in Section 505-1(g)(2)(A) of FDCA.

If you plan to distribute an authorized generic product under this NDA, you will also need to submit a REMS, REMS supporting document, and any required appended documents for that authorized generic, to this NDA. In other words, you must submit a complete proposed REMS that relates only to the authorized generic product. Review and approval of the REMS is required before you may market your product.

Prominently identify submissions containing REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission:

NDA 200535 REMS ASSESSMENT

**NEW SUPPLEMENT FOR NDA 200535
PROPOSED REMS MODIFICATION
REMS ASSESSMENT**

**NEW SUPPLEMENT FOR (NEW INDICATION FOR USE)
FOR NDA 200535
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)**

If you do not submit electronically, please send 5 copies of REMS-related submissions.

EXPIRATION DATING PERIOD

An expiration dating period of 24 months is granted to Oxycodone Hydrochloride Oral Solution, 100 mg/5 mL (20 mg/mL), stored at 25°C (77°F), [REDACTED] (b) (4). Due to the pending development of the analytical method and acceptance criteria for [REDACTED] (b) (4), any extension of drug product expiry period beyond 24 months may be accomplished only via a prior-approval supplement with adequate supporting data. Note that all stability data should be from drug product samples retained in the container closure approved for marketing, including the child-resistant closure.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Tanya Clayton, Senior Regulatory Project Manager, at (301) 796-0871.

Sincerely,

{See appended electronic signature page}

Sharon Hertz, MD
Deputy Director
Division of Anesthesia and Analgesia
Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosures:
Content of Labeling
Carton Labeling
Container Labeling
Medication Guide
REMS

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

TANYA D CLAYTON
10/20/2010

SHARON H HERTZ
10/20/2010